Hb levels increased from 7.5–8.2 g/dL to 9.5–11.5 g/dL after erythropoietin beta therapy, and there was no evidence of recurrent PRCA after initiating this treatment for 13–20 months. The gene discussed is GSTM1; the disease is pure red-cell aplasia.